Allergy Therapeutics (FRA:HHU) Short Interest


FRA:HHU Allergy Therapeutics PLC FRA:HHU
39 GF Score
Price €0.07
GF Value €0.03
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Allergy Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:HHU vs ZTS, UTHR, VTRS: Short Interest Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Allergy Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Allergy Therapeutics Short Interest vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Allergy Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Allergy Therapeutics's Short Interest falls into.


FRA:HHU
39GF Score
Allergy Therapeutics PLC FRA:HHU
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Allergy Therapeutics (FRA:HHU) Overvalued in 2026?

Based on GuruFocus' analysis, Allergy Therapeutics stock appears to be overvalued. The current stock price of €0.07 is trading 141.7% above its estimated GF Value™ of €0.03. GuruFocus considers Allergy Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:HHU:

  • Short Interest:
  • GF Value™: €0.03 vs. price of €0.07 (141.7% above fair value)
  • GF Score™: 39/100 with 7 warning signs

No single metric tells the full story. See the FRA:HHU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Allergy Therapeutics Business Description

Other Exchanges AGYTF:USAAGY:UKHHU:Germany
Address Dominion Way, Worthing, West Sussex, GBR, BN14 8SA
Allergy Therapeutics plc is an international biotechnology group focused on the diagnosis and treatment of allergic disorders through immunotherapies that target the underlying cause of disease. Its portfolio includes Pollinex, Pollinex Quattro, Acarovac, Tyrosine S/TU, Venomil, Oralvac and other allergy immunotherapy products, supported by R&D programmes such as Grass MATA MPL and VLP Peanut. The Group operates in a single class of business, being the manufacture and sale of allergy-related medicines, and maintains centralised manufacturing and research and development capabilities in the UK. Its geographical presence covers Central Europe (Germany, Austria, Switzerland and the Netherlands), Southern Europe (Spain and Italy) and the Rest of the World (including the UK).
39GF Score

Get the complete analysis for FRA:HHU

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.07
Price
€0.03
GF Value